This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Amicus, Amarin, Oncothyreon

BOSTON ( TheStreet) -- This is the last Biotech Stock Mailbag for 2012. I've been writing this column for six years, but without your emails and tweets, the Mailbag wouldn't be possible. Thank you for all your comments, questions and criticism. Merry Christmas and Happy New Year. The Mailbag will return, rested and re-energized, in 2013.

@biotechmoney18 writes, "Hey, AF! Nice call on bullish $FOLD on 11/30. Maybe you should do some real DD instead of listening to your bleep boss."

I got Amicus Therapeutics (FOLD - Get Report) wrong. I regret the bad call.

I expected Amicus' Fabry disease drug Amigal to demonstrate a statistically significant kidney response compared to placebo at six months -- the primary endpoint of the pivotal phase III study. Kidney response was defined as 50% reduction or more in kidney GL3 level at six months.

As reported Wednesday night, the 41% kidney response rate for Amigal patients surpassed the 28% response seen in placebo patients, but the difference was not statistically significant. The study failed. Amicus shares fell by nearly half Thursday.

The outcome is absolutely discouraging, and I'm not surprised to see the sharp selloff in Amicus. It's deserved. But I'm also unwilling to write off Amicus because the results of the study are just as frustrating and confusing as they are negative. There seems to be a signal of activity with Amigal that needs more detailed explanation. Unfortunately, Amicus chose not to hold a conference call to discuss the study results. I'll blame its partner GlaxoSmithKline (GSK) for that idiotic decision -- typical Big Pharma bull---t.

A full presentation of the Amigal study results is scheduled for the Lysosomal Disease Network World Symposium from Feb. 12 to 15.

The 28% response rate in placebo patients is much higher than expected. Why? Female Fabry patients have a lot more variability in GL3 levels, so this may have contributed to the miss. Two-thirds of the enrolled patients in the study were female, but we don't know the breakdown of female responders in each arm.

Lower-than-expected baseline GL3 levels (skewed toward the placebo patients) may also have played a role in boosting the placebo response rate higher than normal. Or, variability in the kidney biopsy samples, from which response is determined. Again, we don't know the answer but should get more clarity at the medical conference in February.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AMRN $2.33 0.00%
FOLD $12.00 0.00%
ONTY $1.72 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs